180 related articles for article (PubMed ID: 36162075)
1. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
Sainas S; Giorgis M; Circosta P; Poli G; Alberti M; Passoni A; Gaidano V; Pippione AC; Vitale N; Bonanni D; Rolando B; Cignetti A; Ramondetti C; Lanno A; Ferraris DM; Canepa B; Buccinnà B; Piccinini M; Rizzi M; Saglio G; Al-Karadaghi S; Boschi D; Miggiano R; Tuccinardi T; Lolli ML
J Med Chem; 2022 Oct; 65(19):12701-12724. PubMed ID: 36162075
[TBL] [Abstract][Full Text] [Related]
2. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
Sainas S; Giorgis M; Circosta P; Gaidano V; Bonanni D; Pippione AC; Bagnati R; Passoni A; Qiu Y; Cojocaru CF; Canepa B; Bona A; Rolando B; Mishina M; Ramondetti C; Buccinnà B; Piccinini M; Houshmand M; Cignetti A; Giraudo E; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
J Med Chem; 2021 May; 64(9):5404-5428. PubMed ID: 33844533
[TBL] [Abstract][Full Text] [Related]
3. Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors.
Sainas S; Pippione AC; Lupino E; Giorgis M; Circosta P; Gaidano V; Goyal P; Bonanni D; Rolando B; Cignetti A; Ducime A; Andersson M; Järvå M; Friemann R; Piccinini M; Ramondetti C; Buccinnà B; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
J Med Chem; 2018 Jul; 61(14):6034-6055. PubMed ID: 29939742
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds.
Sainas S; Pippione AC; Giorgis M; Lupino E; Goyal P; Ramondetti C; Buccinnà B; Piccinini M; Braga RC; Andrade CH; Andersson M; Moritzer AC; Friemann R; Mensa S; Al-Kadaraghi S; Boschi D; Lolli ML
Eur J Med Chem; 2017 Mar; 129():287-302. PubMed ID: 28235702
[TBL] [Abstract][Full Text] [Related]
5. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.
Zhou J; Yiying Quah J; Ng Y; Chooi JY; Hui-Min Toh S; Lin B; Zea Tan T; Hosoi H; Osato M; Seet Q; Ooi LAG; Lindmark B; McHale M; Chng WJ
Haematologica; 2020 Sep; 105(9):2286-2297. PubMed ID: 33054053
[TBL] [Abstract][Full Text] [Related]
6. An alternative conformation of the N-terminal loop of human dihydroorotate dehydrogenase drives binding to a potent antiproliferative agent.
Alberti M; Poli G; Broggini L; Sainas S; Rizzi M; Boschi D; Ferraris DM; Martino E; Ricagno S; Tuccinardi T; Lolli ML; Miggiano R
Acta Crystallogr D Struct Biol; 2024 Jun; 80(Pt 6):386-396. PubMed ID: 38805244
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells.
Wu D; Wang W; Chen W; Lian F; Lang L; Huang Y; Xu Y; Zhang N; Chen Y; Liu M; Nussinov R; Cheng F; Lu W; Huang J
Haematologica; 2018 Sep; 103(9):1472-1483. PubMed ID: 29880605
[TBL] [Abstract][Full Text] [Related]
8. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
Sykes DB; Kfoury YS; Mercier FE; Wawer MJ; Law JM; Haynes MK; Lewis TA; Schajnovitz A; Jain E; Lee D; Meyer H; Pierce KA; Tolliday NJ; Waller A; Ferrara SJ; Eheim AL; Stoeckigt D; Maxcy KL; Cobert JM; Bachand J; Szekely BA; Mukherjee S; Sklar LA; Kotz JD; Clish CB; Sadreyev RI; Clemons PA; Janzer A; Schreiber SL; Scadden DT
Cell; 2016 Sep; 167(1):171-186.e15. PubMed ID: 27641501
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.
Madak JT; Cuthbertson CR; Miyata Y; Tamura S; Petrunak EM; Stuckey JA; Han Y; He M; Sun D; Showalter HD; Neamati N
J Med Chem; 2018 Jun; 61(12):5162-5186. PubMed ID: 29727569
[TBL] [Abstract][Full Text] [Related]
11.
Cisar JS; Pietsch C; DeRatt LG; Jacoby E; Kazmi F; Keohane C; Legenski K; Matico R; Shaffer P; Simonnet Y; Tanner A; Wang CY; Wang W; Attar R; Edwards JP; Kuduk SD
J Med Chem; 2022 Aug; 65(16):11241-11256. PubMed ID: 35925768
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
Knecht W; Henseling J; Löffler M
Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
[TBL] [Abstract][Full Text] [Related]
13. Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication.
Luganini A; Sibille G; Mognetti B; Sainas S; Pippione AC; Giorgis M; Boschi D; Lolli ML; Gribaudo G
Antiviral Res; 2021 May; 189():105057. PubMed ID: 33716051
[TBL] [Abstract][Full Text] [Related]
14. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
[TBL] [Abstract][Full Text] [Related]
15. The Novel
Sibille G; Luganini A; Sainas S; Boschi D; Lolli ML; Gribaudo G
Viruses; 2022 Oct; 14(10):. PubMed ID: 36298835
[TBL] [Abstract][Full Text] [Related]
16. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia.
Sykes DB
Expert Opin Ther Targets; 2018 Nov; 22(11):893-898. PubMed ID: 30318938
[No Abstract] [Full Text] [Related]
17. A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma.
Li C; Zhou Y; Xu J; Zhou X; Huang Z; Zeng T; Yang X; Tao L; Gou K; Zhong X; Chen Q; Luo Y; Zhao Y
Eur J Med Chem; 2022 Aug; 238():114489. PubMed ID: 35640328
[TBL] [Abstract][Full Text] [Related]
18. Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation.
Saunthararajah Y
Haematologica; 2020 Sep; 105(9):2191-2193. PubMed ID: 33054042
[No Abstract] [Full Text] [Related]
19. Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.
So J; Lewis AC; Smith LK; Stanley K; Franich R; Yoannidis D; Pijpers L; Dominguez P; Hogg SJ; Vervoort SJ; Brown FC; Johnstone RW; McDonald G; Ulanet DB; Murtie J; Gruber E; Kats LM
EMBO Mol Med; 2022 Jul; 14(7):e15203. PubMed ID: 35514210
[TBL] [Abstract][Full Text] [Related]
20. Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.
Zhang L; Zhang J; Wang J; Ren C; Tang P; Ouyang L; Wang Y
Eur J Med Chem; 2022 Mar; 232():114176. PubMed ID: 35151222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
